Adaptive Biotechnologies, a Seattle-based biotechnology company, experienced a significant decline in its stock value after announcing a strategic review. This review, conducted in collaboration with Goldman Sachs, aims to maximize the value of the company’s MRD and Immune Medicine businesses. As a result, shares of Adaptive Biotechnologies dropped 35% to a new all-time low of $2.77 in midday trading. With a 63% decrease in stock value this year, the company faces an uphill battle.
Adaptive Biotechnologies reported a widened loss in the third quarter, recording a loss of $50.3 million, or 35 cents a share. This compares to a loss of $45.3 million, or 32 cents a share, in the same period the previous year. FactSet analysts were expecting a loss of 33 cents per share. Additionally, the company’s revenue decreased by 21% to $37.9 million, mainly due to a more than 50% drop in revenue from its Immune Medicine business.
As part of its strategic review, Adaptive Biotechnologies has revised its 2023 guidance to exclude revenue from its Immune Medicine business. This decision reflects the company’s efforts towards optimizing its operations and aligning its focus on key areas of growth and profitability.
In light of these challenges, Adaptive Biotechnologies must navigate through the current market conditions to secure a more stable future. The company’s partnership with Goldman Sachs and its ongoing strategic review will play a crucial role in determining its path forward.